Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BRCA1 mutation testing for Japanese patients with ovarian cancer in breastcancer screening
Autore:
Yamashita, Y; Sagawa, T; Fujimoto, T; Sugawara, T; Yamada, H; Hoshi, N; Sakuragi, N; Ishioka, C; Fujimoto, S;
Indirizzi:
Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Kita Ku, Sapporo, Hokkaido,Japan Hokkaido Univ Sapporo Hokkaido Japan l, Kita Ku, Sapporo, Hokkaido,Japan Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi, Japan Tohoku Univ Sendai Miyagi Japan in Oncol, Aoba Ku, Sendai, Miyagi, Japan
Titolo Testata:
BREAST CANCER RESEARCH AND TREATMENT
fascicolo: 1, volume: 58, anno: 1999,
pagine: 11 - 17
SICI:
0167-6806(199911)58:1<11:BMTFJP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
GERM-LINE MUTATIONS; FOLLOW-UP; HEREDITARY; WOMEN; GENE; INDIVIDUALS; FEATURES; CARRIERS; FAMILIES;
Keywords:
BRCA1; breast cancer screening; breast ovarian cancer syndrome; familial ovarian cancer; genetic testing; ovarian cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Sagawa, T Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Kita Ku, Sapporo,Hokkaido,Japan Hokkaido Univ Sapporo Hokkaido Japan , Sapporo, Hokkaido,Japan
Citazione:
Y. Yamashita et al., "BRCA1 mutation testing for Japanese patients with ovarian cancer in breastcancer screening", BREAST CANC, 58(1), 1999, pp. 11-17

Abstract

From February 1996 to April 1998, 2967 women received screening for breastcancer in the gynecologic ambulatory practice ofthe Hokkaido University Hospital. In 116 Japanese women with epithelial ovarian cancer, mutation analysis of BRCA1 exon 11 in genomic DNA was performed by the stop codon (SC) assay and DNA sequence analysis. Clinicopathological factors were also investigated in these patients. The aim of this study was to examine the advantages of performing BRCA1 mutation testing for ovarian cancer patients duringbreast cancer screening. We achieved a high detection rate (6.0) of patients with germline mutations in BRCA1. The high frequencies of breast ovariancancer syndrome, serous adenocarcinoma, high histological grades, advancedFIGO stages, and breast cancer as double cancer were found to be characteristic of ovarian cancer with germline mutations in BRCA1. These characteristics may assist physicians in selecting BRCA1 mutation testing for ovarian cancer patients. The mean age at diagnosis of ovarian cancer was 51.0 and 51.2 years in the groups with and without mutation, respectively, and no difference was found in age at diagnosis. All of the nine living female mutation carriers were offered the options of increased surveillance or prophylactic surgery, and all chose the former. We have performed breast cancer screening and/or ovarian cancer screening every 6 months for these carriers. This may allow another advantage in establishing a relationship of mutual trust with a patient from a series of responsible follow-ups.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 16:08:02